GeneDx Holdings Shares Drop 16.6% Following Lowered Growth Targets
GeneDx Holdings (WGS) saw its stock price plummet by 16.6% on November 10, 2026, after the company lowered its 2026 exome and genome volume growth targets. While third-quarter revenue rose 5% to $123.1 million—meeting Wall Street expectations—the core testing volume of 32,134 results grew by only 25%, missing the previously projected minimum of 29.2%. Management attributed the volume shortfall to new upfront paperwork designed to filter out lower-value orders in favor of higher-margin tests. Despite keeping revenue forecasts intact, this marks the company's third downward growth revision this year, leading investors to react negatively to the decelerating momentum in its core business segment.
Topics: biotechnology earnings miss genetic testing growth target revision
Read the full article at Motley Fool
Part of the story GeneDx Holdings Shares Drop 16.6% Following Lowered Growth Targets (2 articles)